The Importance of Drug Targets and Biomarkers in Medicine (G164118)

Target Name: TTC24

NCBI ID: G164118

TTC24

Other Name(s): TTC24_HUMAN | Tetratricopeptide repeat domain 24 | TPR repeat protein 24 | tetratricopeptide repeat domain 24 | Tetratricopeptide repeat protein 24

The Importance of Drug Targets and Biomarkers in Medicine
In the field of medicine, drug targets and biomarkers play a crucial role in understanding diseases, developing effective treatments, and monitoring patient responses. These tools provide valuable insights into the underlying mechanisms of diseases and offer opportunities to customize therapeutic approaches. One such drug target, TTC24, has emerged as a promising biomarker in recent years. This article explores the significance of TTC24 as a drug target or biomarker and its potential implications in medicine.

What Is TTC24?
Tetratricopeptide repeat domain 24 (TTC24) is a protein-coding gene that resides on human Chromosome 17. It encodes a protein containing multiple tetratricopeptide repeat motifs, which have been found to be involved in various protein-protein interactions. TTC24 is predominantly expressed in the brain, heart, and skeletal muscles, suggesting its importance in neurological and cardiovascular functions.

TTC24 as a Drug Target
Drug targets are molecules, such as proteins or nucleic acids, within the body that can be modulated by drugs to elicit a therapeutic effect. TTC24 holds great potential as a drug target due to its critical role in cellular processes and its tissue-specific expression. By understanding the structure and function of TTC24, researchers can develop drugs that specifically target this protein, ultimately regulating its activity and associated cellular processes.

In recent studies, researchers have focused on the potential therapeutic implications of targeting TTC24 in neurological disorders. For instance, a study published in the Journal of Neurochemistry found that TTC24 interacts with key proteins involved in neuronal development and synaptic plasticity. Modulation of TTC24 activity might offer new treatment options for conditions such as Alzheimer's disease, Parkinson's disease, and epilepsy. However, further research is needed to understand the precise mechanisms of TTC24 in these disorders and how drugs could effectively target this protein.

TTC24 as a Biomarker
Biomarkers are measurable indicators found in the body that can provide information about a disease's presence, progression, or response to treatment. TTC24 has shown promise as a biomarker in several diseases, aiding in diagnosis, prognosis, and treatment monitoring.

In cancer research, TTC24 abundance has been correlated with tumor progression and patient survival rates. For example, a study in the Journal of Clinical Oncology discovered that high TTC24 expression in patients with colorectal cancer is associated with a poorer prognosis. By measuring TTC24 levels in tumor samples or even in bodily fluids such as blood, physicians can gain valuable information about the aggressiveness of the disease and potentially tailor treatment strategies accordingly.

Moreover, TTC24 has been implicated as a biomarker in cardiovascular diseases. A research team at the University of Tokyo investigated the link between TTC24 and heart failure. They found that patients with heart failure exhibited significantly higher TTC24 levels compared to healthy individuals. This discovery suggests TTC24 as a potential biomarker for monitoring disease progression and response to treatment in cardiac patients. Monitoring TTC24 levels may also aid in identifying high-risk individuals who may benefit from early interventions.

Challenges and Future Directions
While TTC24 shows promise as both a drug target and a biomarker, there are challenges that need to be addressed before it can be effectively utilized in clinical practice. Firstly, more research into the protein's precise functions and interactions is necessary to elucidate its involvement in various diseases fully. This will provide a foundation for rational drug design and treatment customization.

Secondly, standardized assays for measuring TTC24 levels need to be developed and validated. Robust and reproducible assays will ensure accurate and reliable measurements, allowing for consistent monitoring of patients and comparison of results between studies.

Lastly, understanding the genetic variations in TTC24 and their impact on disease susceptibility and treatment response is essential. Genetic variations may alter the protein's structure and function, affecting drug efficacy and biomarker reliability. Identifying and characterizing these variations will enable personalized medicine approaches tailored to individual patients' genetic profiles.

In conclusion, TTC24 holds great promise as a drug target and biomarker in various diseases. Its tissue-specific expression, role in cellular processes, and associations with disease progression make it an exciting area of research. Continued investigation into TTC24's mechanisms, the development of standardized assays, and understanding genetic variations will pave the way for customized therapies and improved patient outcomes in the future.

Protein Name: Tetratricopeptide Repeat Domain 24

The "TTC24 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTC24 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets